BGM Group Ltd.
BGM Healthcare Drug Manufacturers Specialty & Generic
BGM Group Ltd.’s revenue for fiscal 2025 (year ended September 2025) was $37.9 million, up 51.1% from fiscal 2024.
Follow BGM
BGM Group Ltd. (BGM) Altman Z-score
BGM Group Ltd.'s Altman Z-score for fiscal 2025 is 498.01, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 498.01 | 380.35 |
| FY2024 | 117.66 | 42.00 |
| FY2023 | 75.66 | (6.25) |
| FY2022 | 81.91 | (52.25) |
| FY2021 | 134.16 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.02 | — | 0.03 | |
| Retained earnings / total assets | (0.04) | — | −0.05 | |
| EBIT / total assets | (0.03) | — | −0.10 | |
| Market value of equity / total liabilities | 830.06 | — | 498.04 | |
| Sales / total assets | 0.09 | — | 0.09 | |
| Altman Z-score | Safe zone | 498.01 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 9.65 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| BGM BGM Group Ltd. | 498× |
| CRDL Cardiol Therapeutics Inc. compare | 3.4× |
| ORGO Organogenesis compare | 3.0× |
| DERM Journey Medical Corporation compare | 1.1× |
| CPIX Cumberland Pharmaceuticals Inc. compare | 0.7× |
| OGI Organigram Global Inc. compare | 0.2× |
| PROCF Sofgen Pharma S.A compare | −1.4× |
| CLVR Clever Leaves Holdings Inc. compare | −9.4× |
| CTOR Citius Oncology, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets